Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pramipexole
Drug ID BADD_D01817
Description Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) [A176867]. It was first approved by the FDA in 1997 [L5882]. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients [A176855], leading to increased difficulty in performing activities of daily living due to symptoms that progress over time [A176858]. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016 [A176861]. This increase may be attributed to an aging population along with other contributing factors [A176861]. In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS) [A176873]. RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs [A176876].
Indications and Usage This drug is indicated for the symptomatic treatment of Parkinson’s disease [FDA label]. This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) [FDA label].
Marketing Status approved; investigational
ATC Code N04BC05
DrugBank ID DB00413
KEGG ID D05575
MeSH ID D000077487
PubChem ID 119570
TTD Drug ID D0G8NN
NDC Product Code 31722-910; 31722-906; 10370-305; 31722-909; 31722-911; 31722-907; 31722-908; 10370-253
UNII 83619PEU5T
Synonyms Pramipexole | 4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazole-diamine | Pramipexol | 2-Amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole | Dexpramipexole | Pramipexol, (R)-isomer | Mirapex | Pramipexol Dihydrobromide, (+-)-isomer | Pramipexol Dihydrochloride, (S)-isomer | Pramipexole Dihydrochloride Anhydrous | Sifrol | SND 919CL2x | SND919CL2x | SND-919CL2x | SND-919 | SND 919 | KNS 760704 | KNS760704 | KNS-760704 | Pramipexol, (+-)-isomer | Pramipexole Dihydrochloride | Pramipexole Hydrochloride Monohydrate | 2-Amino-6-propylaminotetrahydrobenzothiazole | 2 Amino 6 propylaminotetrahydrobenzothiazole | 6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate
Chemical Information
Molecular Formula C10H17N3S
CAS Registry Number 104632-26-0
SMILES CCCNC1CCC2=C(C1)SC(=N2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Substance-induced psychotic disorder12.03.01.053; 19.03.01.0070.000319%-
Hepatic cancer09.04.02.008; 16.07.02.004---
Anal incontinence07.01.06.029; 17.05.01.021--
Frustration tolerance decreased19.04.02.0160.000319%-
Gambling disorder19.07.06.0150.004545%-
Alcohol interaction08.06.03.0030.000159%-
Eosinophilic fasciitis01.02.04.010; 10.04.02.008; 15.06.01.0130.000319%-
Impulsive behaviour19.18.01.0010.000319%-
Jealous delusion19.10.01.0060.001387%-
Paraphilia19.08.06.0020.000159%-
Persecutory delusion19.10.01.0070.000159%-
Placental insufficiency18.05.02.006; 24.04.12.0020.000239%-
Social anxiety disorder19.06.03.0100.000159%-
Somatic delusion19.10.01.0080.000159%-
Dopamine dysregulation syndrome17.01.05.012; 19.07.06.0090.000510%-
Compulsive hoarding19.06.05.0090.000319%-
Camptocormia15.03.05.004; 17.02.05.0530.000159%-
Executive dysfunction19.21.02.0100.000159%-
Parkinsonism hyperpyrexia syndrome08.06.02.018; 17.01.05.0130.000399%-
Dropped head syndrome15.05.06.002; 17.05.03.0150.000159%-
Postural tremor17.01.06.0090.000159%-
Behaviour disorder19.01.01.0050.000399%-
Cerebral salt-wasting syndrome14.05.04.011; 17.02.10.0290.000239%-
Congenital musculoskeletal disorder of spine03.11.04.007; 15.11.04.007---
Defaecation disorder07.02.03.0080.000159%-
Delusion of replacement19.10.01.0100.000159%-
Delusional disorder, jealous type19.03.03.0050.000239%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.000431%-
Gait inability08.01.02.011; 17.02.05.0690.000239%-
Heavy menstrual bleeding21.01.03.005---
The 22th Page    First    Pre   22 23    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene